Progress of chimeric antigen receptor in childhood acute T-lymphoblastic leukemia
10.3760/cma.j.issn.1673-4408.2022.01.001
- VernacularTitle:儿童急性T细胞白血病嵌合抗原受体研究进展
- Author:
Hongbo HE
1
;
Chao GAO
;
Huyong ZHENG
Author Information
1. 国家儿童医学中心 首都医科大学附属北京儿童医院血液病中心 儿童血液病与肿瘤分子分型北京市重点实验室 儿科学国家重点学科 儿科重大疾病研究教育部重点实验室 100045
- Keywords:
Children;
Acute lymphoblastic leukemia;
Chimeric antigen receptor
- From:
International Journal of Pediatrics
2022;49(1):1-5
- CountryChina
- Language:Chinese
-
Abstract:
Acute lymphoblastic leukemia(ALL)is the most common malignant tumor in childhood, and T-ALL accounts for 10%~15% of all in children with ALL.Based on the application of MICM classification, risk stratification and multi-drugs intensive therapy, the prognosis of children with T-ALL has been improved, but the overall survival rate and event free survival rate are still less than 70%, and the overall survival rate of relapsed / refractory T-ALL is less than 10%.The treatment of T-ALL in children still faces great challenges.CDl9 targeted chimeric antigen receptor(CAR)modified T cells have shown impressive results in children with refractory B-ALL, with remission rate of 70%~90%.The emergence of CAR-T and CAR modified NK cells(CAR-NK)targeted therapy is expected to improve the prognosis of T-ALL in children.This article reviews the latest progress of CAR-T and CAR-NK in children with T-ALL.
